© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
New Large-Scale Study Challenges Previous Research on Menopause and Brain Structure
October 21, 2025
New research presented at TMS 2025 suggests menopause stage does not accelerate brain volume loss—age does. Study author discusses clinical implications for PCPs.
Early Natural Menopause Associated With Increased Metabolic Syndrome Risk, According to New Research
October 21, 2025
TMS 2025: Early natural menopause significantly raises the risk of metabolic syndrome, highlighting the need for proactive health interventions in at-risk women.
Pooled Safety Analysis Supports Elinzanetant for Vasomotor Symptoms Through 52 Weeks
October 21, 2025
Analysis of 4 clinical trials, including 3 from the phase 3 OASIS development program, found treatment-emergent AEs comparable between elinzanetant and placebo.
Plasma Biomarkers Achieve High Accuracy for Confirmatory Aβ Positivity in Eligibility Test for DMT in Alzheimer Disease
October 21, 2025
Plasma assays combining p-tau217 and Aβ42/40 accurately confirm AD, supporting patient eligibility for anti-amyloid disease-modifying therapies.
Provider Specialty and Type Drive Divergent Prescribing Patterns for Symptoms of Menopause
October 21, 2025
TMS 2025: Wide variability in practice patterns suggests a need for standardized education across both specialties and provider types to ensure consistent quality of care.
6 Latent Menopausal Phenotypes Identified by Machine Learning in 10-Year SWAN Follow-Up
October 21, 2025
TMS 2025: Machine learning uncovered 6 menopausal phenotypes, linking symptom patterns and metabolic risk and potential for personalized treatment strategies.
Orforglipron Achieves Up to 12% Weight Loss in Obesity Phase 3 Study: Daily Dose
October 21, 2025
Your daily dose of the clinical news you may have missed.
Oral Semaglutide Wins Approval to Reduce Risk of MACE in Adults with T2D at High Risk
October 20, 2025
The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.
FDA Approves TSLP Inhibitor Tezepelumab for Chronic Rhinosinusitis With Nasal Polyps
October 20, 2025
Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.
Grail Reports Strong Performance for Galleri Blood Test Ahead of FDA Submission
October 20, 2025
GRAIL's PATHFINDER 2 study shows Galleri blood test detected 7 times more cancers when added to standard screenings, with 99.6% specificity and low false positives.